From Pharmacovigilance to Clinical Care Optimization.
Big Data / September 1, 2014
Leo Anthony Celi / Edward Moseley / Christopher Moses / Padhraig Ryan / Melek Somai / David Stone / Kai-ou Tang
In order to ensure the continued, safe administration of pharmaceuticals, particularly those agents that have been recently introduced into the market, there is a need for improved surveillance after product release. This is particularly so because drugs are used by a variety of patients whose particular characteristics may not have been fully captured in the original market approval studies.